The Burkholderia Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Burkholderia Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued products.
GlobalData tracks 19 drugs in development for Burkholderia Infections by 19 companies/universities/institutes. The top development phase for Burkholderia Infections is preclinical with nine drugs in that stage. The Burkholderia Infections pipeline has 14 drugs in development by companies and five by universities/ institutes. Some of the companies in the Burkholderia Infections pipeline products market are: Planet Biotechnology, EpiVax and Defence Science and Technology Laboratory.
The key targets in the Burkholderia Infections pipeline products market include Interferon Gamma Receptor 1, Interferon Gamma Receptor 2, and Leucine tRNA Ligase Cytoplasmic.
The key mechanisms of action in the Burkholderia Infections pipeline product include DNA Topoisomerase IV Inhibitor with one drug in Phase I. The Burkholderia Infections pipeline products include four routes of administration with the top ROA being Intravenous and ten key molecule types in the Burkholderia Infections pipeline products market including Small Molecule, and Subunit Vaccine.
Burkholderia Infections overview
Burkholderia is a genus of Pseudomonadota whose pathogenic members include the Burkholderia cepacia complex, which attacks humans and Burkholderia mallei, responsible for glanders, a disease that occurs mostly in horses and related animals; Burkholderia pseudomallei, causative agent of melioidosis; and Burkholderia cepacia, an important pathogen of pulmonary infections in people with cystic fibrosis (CF).
For a complete picture of Burkholderia Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
